HGS seeks to apply science and medicine to bring innovative drugs to patients with unmet medical needs.
As of August 2009, The company is poised for the market with a clinical pipeline that includes three products in late-stage development:
BENLYSTA™ (formerly LymphoStat-B®) has successfully completed one of two pivotal Phase 3 trials in systemic lupus, and we expect results from the second Phase 3 trial of BENLYSTA in November 2009;
ZALBIN™ (formerly Albuferon®) has successfully completed two Phase 3 trials in chronic hepatitis C, and we expect the filing of global marketing applications for ZALBIN in fall of this year;
Raxibacumab (ABthraxâ„¢) is currently pending priority review by FDA for inhalation anthrax.
